Affordable Care Act, Drug Pricing, Centers for Medicare & Medicaid Services (CMS)

Recent Developments in Pharmacy-Related Legislation and Regulations

Wiley Rein LLP on 5/15/2024

Over the last two months, there has been a steady influx of regulatory and legislative efforts regarding drug pricing and the pharmacy industry. To streamline your review, we summarize below a few noteworthy developments that...more

Holland & Knight Health Dose: March 12, 2024

Holland & Knight LLP on 3/14/2024

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector....more

McDermottPlus Check-Up: June 16, 2023

McDermott+ on 6/16/2023

The House and Senate were both in session this week, with healthcare activity continuing at the committee level. The House Energy and Commerce Committee held hearings on the Pandemic and All Hazards Preparedness Act (PAHPA)...more

Several New Group Health Plan Reporting Deadlines Are Approaching – Check Out Our CAA/Price Transparency Checklist

Foley & Lardner LLP on 12/16/2022

This year, Foley’s Health Benefits Practice has released multiple alerts on several of the new group health plan requirements set forth by the Consolidated Appropriations Act of 2021 (CAA) and the Transparency in Coverage...more

Healthcare Regulatory Check-Up Newsletter | August 2022 Recap

McDermott Will & Emery on 9/1/2022

This issue of McDermott’s Healthcare Regulatory Check-Up highlights significant enforcement activity between July 21 and August 20, 2022. Key updates include a case in which the US Court of Appeals for the Eighth Circuit...more

With Inflation Reduction Act Signed, Other Health Policy Issues Ahead for Congress

Holland & Knight LLP on 8/17/2022

Congress ended a busy work period after passing the Inflation Reduction Act (IRA) last week. This Holland & Knight alert summarizes the healthcare provisions in the IRA and provides an outlook on health policy issues that may...more

Holland & Knight Health Dose: July 19, 2022

Holland & Knight LLP on 7/20/2022

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector. This week's topics include: ...more

Healthcare & Life Sciences: Drug Pricing Digest - July 2022 #2

Latham & Watkins LLP on 7/20/2022

Drug Pricing Initiatives: Democrats renewed their efforts to pass drug pricing reform measures in the form of a revised H.R. 5376 (the Build Back Better Act, or BBBA). Democrats intend to adopt the BBBA as part of the budget...more

Enforcing Medicaid’s Guarantee of Access to Prescription Drugs

Foley Hoag LLP - Medicaid and the Law on 3/15/2022

Over the years, we’ve written about the difficulties in challenging the entitlement to Medicaid in the federal courts. In light of a series of Supreme Court decisions dating back to 1990, the pathway for an aggrieved Medicaid...more

2022 Congressional Outlook and Top 10 Federal Health Policy Issues to Watch

Holland & Knight LLP on 1/7/2022

As Congress reconvenes, it faces a packed agenda in a legislative year that will be shortened by the upcoming midterm elections and remains buffeted by the persistent coronavirus pandemic. The list of healthcare priorities is...more

House Democrats Outline Health Care ‎Legislative Priorities

Locke Lord LLP on 9/14/2021

On September 9, 2021, the U.S. House of Representatives Energy and Commerce Committee released their health care proposals for the Build Back Better Act. On September 10, 2021, the Ways and Means Committee released a summary...more

The Courts and Healthcare Policy - August 2021

McGuireWoods Consulting on 8/10/2021

The courts continue to play an important role in health policy. 2020 saw several notable lawsuits related to the Affordable Care Act (ACA). Several other Trump administration policies were challenged, including Medicare...more

Healthcare & Life Sciences: Drug Pricing Digest - June 2021 #2

Latham & Watkins LLP on 6/22/2021

Supreme Court Upholds Affordable Care Act: On June 17, 2021, the Supreme Court ruled 7 to 2 to dismiss for lack of standing a challenge to the Affordable Care Act (ACA) brought by Texas and other states. The states had...more

The American Families Plan & A Call for Drug Pricing Legislation

Mintz - Health Care Viewpoints on 5/11/2021

On April 28, 2021, President Biden gave his first address to Congress and announced the American Families Plan (AFP or the Act). The AFP follows the 1.9 trillion-dollar stimulus, the American Rescue Plan Act, signed into law...more

Washington Healthcare Update - April 2021 #3

McGuireWoods Consulting on 4/27/2021

This week in Washington: Andrea Palm’s nomination for HHS Deputy Secretary Advances out of Senate Finance Committee, Chiquita Brooks-LaSure’s nomination deadlocked....more

Senate Finance Committee Holds Confirmation Hearing For Top Biden HHS Nominees

ArentFox Schiff on 4/16/2021

Deputy Secretary and CMS Administrator Picks Would Fill Two Critical Policy Positions - On Thursday, the Senate Finance Committee held a confirmation hearing for two of the most important health policy officials nominated...more

Relevant Highlights: Hearing to Consider the Nomination of Chiquita Brooks-LaSure to be Administrator for the Centers for Medicare...

Foley & Lardner LLP on 4/16/2021

This morning, the United States Senate Committee on Finance questioned Pres. Biden’s nominee, Chiquita Brooks-LaSure, for Administrator for Centers for Medicare and Medicaid Services (CMS), as well as Andrea Palm, the nominee...more

The Courts and Healthcare Policy

McGuireWoods Consulting on 2/2/2021

2020 saw the courts continuing to play an important role in health policy with several notable lawsuits related to the Affordable Care Act (ACA). Several other Trump administration policies were challenged, including Medicare...more

Post-Election 2020: Healthcare Priorities Under a Biden Administration

Groom Law Group, Chartered on 12/15/2020

The dust has settled and the 2020 election has concluded with former Vice President Biden poised to become president. At the same time, Democratic control of the House of Representatives has narrowed to the smallest margin...more

HRSA Publishes Long-Awaited (and Long-Overdue) 340B Program Alternative Dispute Resolution Process Final Rule

K&L Gates LLP on 12/14/2020

On Thursday, 10 December 2020, the Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA) issued a pre-publication copy of the long-awaited 340B Drug Pricing Program Alternative...more

The Fate of the Trump Administration’s Controversial Most Favored Nation Drug Pricing Model Is Unclear Given Mounting Legal...

Polsinelli on 12/10/2020

On November 27, 2020, CMS published its Most Favored Nation (MFN) Model Interim Final Rule (IFR) that seeks to lower the amount paid for 50 high-cost Medicare Part B drugs to the lowest price that drug manufacturers receive...more

Patient Protection and Affordable Care Act (PPACA) › Drug Pricing › Centers for Medicare & Medicaid Services (CMS)